Literature DB >> 27389467

Measuring quality of life in acute myeloid leukemia: limitations and future directions.

Sarah A Buckley1, Stephanie J Lee2,3, Roland B Walter2,4,5.   

Abstract

Entities:  

Keywords:  Acute myeloid leukemia; clinical trial; endpoint; patient-reported outcomes; quality of life

Mesh：

Year:  2016        PMID： 27389467      PMCID： PMC5147739          DOI： 10.1080/17474086.2016.1211006

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


× No keyword cloud information.
  16 in total

1.  Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia.

Authors:  H Mohamedali; H Breunis; N Timilshina; J M Brandwein; V Gupta; M D Minden; M Li; G Tomlinson; R Buckstein; S M H Alibhai
Journal:  Leuk Res       Date:  2012-06-21       Impact factor: 3.156

Review 2.  Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN.

Authors:  B E Shaw; S J Lee; M M Horowitz; W A Wood; J D Rizzo; K E Flynn
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

3.  U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.

Authors:  Albert Deisseroth; Edvardas Kaminskas; Joseph Grillo; Wei Chen; Haleh Saber; Hong L Lu; Mark D Rothmann; Satjit Brar; Jian Wang; Christine Garnett; Julie Bullock; Laurie B Burke; Atiqur Rahman; Rajeshwari Sridhara; Ann Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2012-04-27       Impact factor: 12.531

4.  Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation.

Authors:  William A Wood; Allison M Deal; Amy Abernethy; Ethan Basch; Claudio Battaglini; Yoon Hie Kim; Julia Whitley; Charlotte Shatten; Jon Serody; Thomas Shea; Bryce B Reeve
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-16       Impact factor: 5.742

5.  Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy--Leukemia (FACT-Leu) questionnaire.

Authors:  David Cella; Sally E Jensen; Kimberly Webster; Du Hongyan; Jin-Shei Lai; Steven Rosen; Martin S Tallman; Susan Yount
Journal:  Value Health       Date:  2012-12       Impact factor: 5.725

Review 6.  Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?

Authors:  Laura Cannella; Giovanni Caocci; Marc Jacobs; Marco Vignetti; Franco Mandelli; Fabio Efficace
Journal:  Crit Rev Oncol Hematol       Date:  2015-08-01       Impact factor: 6.312

7.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Authors:  D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

8.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

9.  Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP).

Authors:  C Rodary; V Pezet-Langevin; S Garcia-Acosta; T Lesimple; A Lortholary; M C Kaminsky; J Bennouna; S Culine; H Bourgeois; Karim Fizazi
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

10.  Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia.

Authors:  Shabbir M H Alibhai; Marc Leach; Vikas Gupta; George A Tomlinson; Joseph M Brandwein; Fernando Suarez Saiz; Mark D Minden
Journal:  Crit Rev Oncol Hematol       Date:  2008-09-07       Impact factor: 6.312
View more
  5 in total

1.  Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada.

Authors:  Sonya Cressman; Donna E Hogge; Mark D Minden; Stephen Couban; Aly Karsan; Raewyn Broady; Emily McPherson; Khalif Halani; Jing Yi Weng; Stuart J Peacock
Journal:  EJHaem       Date:  2020-07-10

2.  Quality of life from the perspective of the patient with acute myeloid leukemia.

Authors:  Sarah A Buckley; Diana Jimenez-Sahagun; Megan Othus; Roland B Walter; Stephanie J Lee
Journal:  Cancer       Date:  2017-09-07       Impact factor: 6.860

3.  All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature.

Authors:  Fabio Forghieri; Sara Bigliardi; Chiara Quadrelli; Monica Morselli; Leonardo Potenza; Ambra Paolini; Elisabetta Colaci; Patrizia Barozzi; Patrizia Zucchini; Giovanni Riva; Daniela Vallerini; Ivana Lagreca; Roberto Marasca; Franco Narni; Adriano Venditti; Maria Paola Martelli; Brunangelo Falini; Francesco Lo Coco; Sergio Amadori; Mario Luppi
Journal:  Clin Case Rep       Date:  2016-10-24

4.  Systematic review of health state utility values for acute myeloid leukemia.

Authors:  Anna Forsythe; Patricia S Brandt; Mike Dolph; Sachin Patel; Adrian Paul J Rabe; Gabriel Tremblay
Journal:  Clinicoecon Outcomes Res       Date:  2018-01-25

5.  Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.

Authors:  Eytan M Stein; Min Yang; Annie Guerin; Wei Gao; Philip Galebach; Cheryl Q Xiang; Subrata Bhattacharyya; Gaetano Bonifacio; George J Joseph
Journal:  Health Qual Life Outcomes       Date:  2018-09-21       Impact factor: 3.186
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.